[ Price : $8.95]
FDAers in CDER and the Oncology Center of Excellence discuss the use of minimal residual disease (MRD) data in hematologic clinica...[ Price : $8.95]
Servier says a Phase 3 clinical trial assessing glioma drug vorasidenib met its primary and secondary endpoints.[ Price : $8.95]
A former Becton Dickinson medical director petitions FDA to scrutinize the companys 2017 510(k) clearance for the GalaForm 3D due...[ Price : $8.95]
FDA announces a 5/2 Webcast entitled Navigating the First ICH Generic Drug Draft Guideline M13A Bioequivalence for Immediate-Rele...[ Price : $8.95]
Still evolving under the same leadership, Dickinsons FDA Webview asks subscribers to help guide our further development and improv...[ Price : $8.95]
FDA clears a PeekMed 510(k) for its Web-based artificial intelligence automated planning solution for use in orthopedic surgery.[ Price : $8.95]
FDA says the main causes of drug shortages continue to be manufacturing quality issues and manufacturing production delays.[ Price : $8.95]
FDA places a clinical hold on Mersana Therapeutics Phase 1 trial of XMT-2056 after the company suspended it due to a recent patien...